$39 Biotech Doubler to Hit $80:
The $1.3 billion medical device company I’m about to name will soon be an $80 stock that you must snap up today for $39.
The stock jumped 146% in the last 12 months and is set to double again this year.
If you fail to add this stock to your holdings now, I guarantee you’ll kick yourself for years.
It’s the only company—and I repeat—the only medical device company that’s 100% dedicated to peripheral nerve repair solutions.
This is why the company’s 12 month’s 146% rise is just the beginning of a bold new profit run.
Once you see my complete profit profile on this company, you’ll quickly agree that …
This Could Be an Easier Double Than Tesla
I’m Timothy Lutts, and that’s a big claim, I know—especially because it’s been one of Cabot’s biggest winners to date.
But not when you see with your own eyes the number of profit triggers this company possesses for Tesla-like growth, then you’ll understand why we added it to our Cabot Small-Cap Confidential holdings. And why I’m urging you to do the same thing before it doubles investors’ money again.
Before I name it, I want to explain how we’ve been able to find these kind of profit-rich, game-changing small-cap stocks with uncanny accuracy—in virtually all markets and at all times, for more than two decades.
How Innovation and Superior Stock Selection
Can Be Your Ticket to a Small Fortune Too
First let me say as the chief investment advisor and futurist for the Cabot organization, it’s not just my job to look 10 to 15 years into the future and show you how to profit, it’s my passion.
That’s why I’m always scanning both the skyline looking for world-changing trends and the horizon looking for the companies at the forefront of these dramatic changes.
I’m proud to say that over the years this forward-thinking approach has led our readers to many investing firsts:
• FIRST to forecast the growth of online retailing, connecting the dots to 1,290% profits in Amazon
• FIRST to see the solar power revolution on the horizon, collecting 270% profits in First Solar in 18 months
• FIRST to see and understand the game-changing technological advantages Apple would bring to the world, banking 746% gains before most Americans even knew the company’s name
• First to alert readers to the revolution in pure-electric cars, handing readers 800% gains in 30 months in TESLA
• FIRST to see the huge monopoly XM-Satellite radio was building in its sectors, handing investors 396% gains in just under two years
That’s why we launched Cabot Small-Cap Confidential in the first place 10 years ago. To bring you more of these ground floor opportunities faster.
I’m proud to say that over the past 10 years, we’ve been able to do just that and double our investors’ money 11 times along the way.
The secret to our success can best be compared to the way an MRI scanner takes pictures inside of your body.
But instead of giving you early warning of a potentially life-threatening disease, my system gives you an advance look at the companies and technologies that can make you rich, months and years before they take off.
That’s because our proprietary stock selection system has been designed not only to identify breakout sales, earnings and profit margin expansion factors …
… but also to identify the specific disruptive, game-changing technologies that most analysts miss and that will ensure a company’s market share and technical superiority for years to come.
Frankly, this is how we banked an 800% gain in Tesla, a 1,290% windfall in Amazon, a 270% gain in First Solar, a 746% profit in Apple and a 396% gain in XM-Satellite Radio.
In other words, we identified these disruptive technologies in their early stages and held on for the ride.
Why My Newest Recommendation Looks
a Lot Like Tesla in the Early Days
Just like Tesla’s battery breakthrough revolutionized the electric car industry, this small-cap medical juggernaut is doing the same thing for the surgical treatment of peripheral nerve damage.
With more than 1.4 million Americans suffering nerve damage every year and 900,000 requiring surgical intervention, this is one medical stock on a growth trajectory that could easily surpass the big profits we made in Tesla.
What makes me say so?
Because unlike the electric car industry, where YOU profit from consumer spending, our company’s surgical profits will be paid for by Medicare and insurance companies—AND the shareholders will reap massive profits along the way.
When you consider the nerve repair market exceeds $1.6 billion annually, and the millions of dollars this company is set to make, I get goosebumps.
Especially because this company is the only—I repeat, the only company that:
1. Is focused on peripheral nerve repair solutions
2. Possesses a product portfolio that addresses all surgical peripheral nerve reconstruction needs
3. Has aggressive sales and marketing staff in place to take advantage of this $1.6B+ medical market opportunity
When you add to that the company’s 75% gross margins, you can begin to understand why this company’s stock price has risen 275% over the past 12 months and 602% over the past two years.
This is why the world’s shrewdest institutions own millions of shares worth over $1 billion. That’s because they see what we do—another Tesla in the making.
That’s why we added this small-cap company to our holdings and why we highly recommend you follow suit.
In fact, I so strongly believe that this new recommendation could ultimately become our next Tesla, I want to give you the name of this company FREE.
1. To show you how profitable it can be to invest in small-cap, emerging technology companies right at the beginning of their biggest growth moves AND before they become front-page news, and
2. To introduce you to our limited-circulation Cabot Small-Cap Confidential investment advisory that targets and profits from these opportunities without you risking a dime.
That way you can see for yourself if our long-term emerging stock investing approach is for you.
Why ONLY 24 Hours?
Because many of our Cabot Small-Cap Confidential recommendations tend to jump soon after we recommend them, as individual investors, hedge funds and institutional investors who know our time-proven track record and follow our recommendations begin to pile into our stocks.
However, by limiting our offer this way, we can help ensure you’ll grab the next wave of profits before the big money piles in and this stock breaks out again—and so you won’t miss a dime’s worth of profits.
BEST OF ALL
By joining us ahead of our 24-hour deadline, you’ll also lock in our best price for the next 90 days—just $2/day.
When you do …
You’ll Also Find 10 More Game Changers
That Could Turn $5,000 into $40,000
Over the Next 30 Months
I speak, for example, of …
• A pure-play security provider that is growing revenue well over 20% and is expanding its portfolio of solutions to address large and rapidly growing markets.
• The emergency communications company that can deliver unique / and critical messaging to governments, individuals and companies during emergencies—on the devices they use the most.
• The cloud-based services company that allows you to access your computer, files and apps from anywhere in the world while instantly backing up your most crucial data.
These are just three of our 10 current game-changing recommendations that we’re targeting for triple-digit profits over the next 30 months.
Individually, each one controls a disruptive breakthrough technology that will turn its industry upside down no differently than Amazon, First Solar, Tesla, Apple and XM-Satellite radio have in theirs.
Together, they will give you the opportunity to turn every $5,000 you invest now into $20,000, $30,000, $40,000 or more over the next 30 months.
This Is Why We Limit Our Subscribers to Just 500—
and Require That Our Investors Not Share, Sell or
Redistribute Our High-Profit Recommendations
A quick look at the 1,290%, 800%, 746% and 396% profits in Amazon, Tesla, Apple and XM-Satellite Radio explains why.
Truth is, if we were to leave our membership open, then the whole world would know—at the same time—which companies we were investing in and you would not be able to buy them while their prices were cheap or before the hedge funds, pension funds and mutual funds jumped in.
That’s also why we require strict confidentiality from our members.
It is precisely this exclusivity and discretion that have helped my subscribers and readers enjoy so many life-changing gains from many of our incredible past recommendations.
This is how we plan to maintain this edge and keep your wealth growing—by keeping our circulation small and our recommendations private.
If this sounds like the kind of exclusive investing advisory, approach, and profits that you’re looking for, you owe it to yourself to accept my incredible offer to get the name of our next Tesla FREE … along with a trial subscription to Cabot Small-Cap Confidential.
Join Now and Save 50%
Just like we limit our advisory to 500 readers, we must limit this introductory offer to the first 50 who say “Yes” today, because we have only 50 open memberships.
Once those final spots are filled, this service will be closed until the next opening.
The reason is simple:
When you consistently deliver these kinds of double- and triple-digit profits year after year, investors stick with you over the long term. We think you will too, or you’ll receive a prorated refund.
In fact, I specifically set it up this way so that you can see results over the long term before you give us your final decision.
That’s because—as you know—the path to 300%, 500% and 1,000% returns doesn’t happen overnight—but over time.
My complete, no-questions-asked, “profit first” money-back guarantee gives you the confidence to invest in our emerging growth plays over the long term, knowing that you can cancel for a prorated refund because you are always protected by our 100% satisfaction guarantee.
If you are already a Cabot subscriber, then you know that’s the same “profit first” approach we’ve honored for 48 years on our other advisories. You can count on it here, too, when you join us at Cabot Small-Cap Confidential.
So if you’ve always wanted to try my Cabot Small-Cap Confidential investing advisory, today is the day.
By simply saying “Yes” to this 100% risk-free opportunity, you’ll get not only the chance to invest in the next Tesla …
… but also the opportunity to lock in my best price ever: just $175 for a 90-day subscription (reg. $350).
That’s not only a 50% savings but also comes to less than $2 a day—and a small investment to make to get in on the ground floor of Wall Street’s most profitable emerging growth companies.
Your introductory $2-a-day price includes:
• A monthly market update that will bring you a panoramic view of what’s going on in the market and how it affects our holdings along with weekly news updates and flash alerts on the stocks that we own and any adjustments for your portfolio
• Institutional-level profit profiles of the exciting new first-mover companies we’re targeting for profits, complete with specific buy and target sell prices
• Weekly updates that will explain how the week’s market changes, government economic reports, earnings releases and/or competitive technologies will affect our investments
• Cabot Cabot Small-Cap Confidential private website, featuring the most recent issue, annual forecast issue and special reports, along with an archive of our past issues and reports dating back eight years
• Personalized investor relations staff to answer your questions every day the market is open, from 9:00 am to 4:00 pm Eastern time
• Tyler Laundon’s private email address should you have any questions about our forecasts or recommendations, along with the promise you will receive a written response directly from him or our staff within 48 hours
• PLUS my 100% satisfaction profit-first guarantee.
This is how Cabot Small-Cap Confidential has become one of the most respected and profitable investment advisories on Wall Street.
As our long-term track record clearly shows, you really can invest in and profit from game-changing companies and technologies when you spot them early and have the patience to hold on for the ride as we do.
My “profit first” guarantee promises just that.
But you’ll need to hurry.
The last time we sent a similar offer to our Cabot family of readers, all our available slots were filled in less than 24 hours.
And at just $2 a day, I expect that same thing to happen this time as well.
So what are you waiting for?
Join us now here at Cabot Small-Cap Confidential today and:
- Check out the explosive profits our small-cap stocks can hand you.
- See how exciting it feels to turn $5,000 into $40,000.
- Take FULL advantage of my 100% satisfaction guarantee to decide if Cabot Small-Cap Confidential is right for you.
Mark my words: Once you grab your first 100% gain, I’ll bet I couldn’t pry your subscription from your hand if I tried.
I promise, it will be one of the most profitable investing decisions of your investing life.
Chief Investment Strategist
P.S. I’ll never forget the day we sold Tesla for a 800% gain and my readers saw a $5,000 investment soar to $40,000!
Or the day I sold Amazon for a 1,290% gain or Apple for a 746% gain or XM-Satellite Radio for a 396% profit.
I know you’ll feel 10-feet tall and bulletproof too, when you get in on the ground floor of my next Tesla TONIGHT and take profits with us here as well.
That’s why I’ve made it as easy as possible for our loyal Cabot readers to give Cabot Small-Cap Confidential a try.
That way you can see the difference our small-cap emerging growth stock advisory can make for your future—and without any risk or obligation to continue if you’re not 100% satisfied with your profits.
That’s why we expect our final open spaces to sell out long before tomorrow’s 24-hour deadline—especially with our first-time-ever $2-a-day price.
Trust your impulse and let your destiny unfold. Join us now here at Cabot Small-Cap Confidential today.
You have nothing to lose and everything to gain.
This special offer ends at midnight.